


**A VSV-based Zika virus vaccine protects mice from lethal challenge**


Jackson Emanuel, Julie Callison, Kimberly A. Dowd, Theodore C. Pierson, Heinz Feldmann,  
and Andrea Marzi

**Supplementary information**




**Figure S1. VSV-ZIKV vaccine protein expression.** VeroE6 cells were infected with ZIKV or VSV vaccines and the supernatant was collected. Western blot analysis confirmed the presence of the viral proteins present in the supernatant of VSV- or ZIKV-infected cells. Lane 1, uninfected control; lane 2, VSV-EBOV; lane 3, VSV-ZIKVprME; lane 4, VSV-ZIKVprMsolE; lane 5, ZIKV.

**A**



**B**



**Figure S2. Maintenance of the ZIKV antigen-encoding sequence in the recombinant VSV-ZIKV genomes.** VSV-ZIKV vectors were serially passaged 10 times and supernatant samples were collected for antigen verification. **(A)** The PCR products of the ZIKV antigen-encoding region of recombinant VSV-ZIKV genome on one agarose gel are shown. Labels indicate the successive passage numbers from passage 2 through 10. The expected band sizes are ~2.0 kb (for VSV-ZIKVprME) and ~1.9 kb (for VSV-ZIKVprMsoIE). **(B)** Western Blot analysis was performed to confirm EBOV GP expression in the supernatant of the infected cells.